Nanobiotix (NANO) | Stock Overview & Key Data
Nanobiotix Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €47.66 on May 18, 2026
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Financial Highlights
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nanobiotix
NANO
|
1.39B Large-cap | 3.58% | -27.34% | 8.48% | 64.63% | 67.58% | 587.64% | 529.63% | 150.41% | 87.73% | 393.55% | 393.55% |
|
Abivax SA
ABVX
|
7.61B Large-cap | -4.54% | -14.08% | -20.62% | -18.33% | -26.00% | 1,368.91% | 434.91% | 184.92% | 1,317.50% | 310.87% | 310.87% |
|
Dbv Technologies
DBV
|
1.02B Large-cap | 12.32% | -4.78% | -7.80% | 2.24% | -2.45% | 89.31% | -17.08% | -70.89% | -94.37% | -62.38% | -62.38% |
|
TheraVet S.A
ALVET
|
N/A | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -89.74% | -98.11% | -99.02% | -99.02% | -99.02% | -99.02% |
|
Inventiva S.A
IVA
|
980.10M Mid-cap | -4.11% | -32.02% | -36.99% | -12.10% | -19.26% | 17.12% | -17.79% | -71.83% | -58.75% | -58.75% | -58.75% |
|
Medincell S.A
MEDCL
|
831.60M Mid-cap | -0.86% | 1.61% | 25.88% | 25.88% | 25.88% | 23.51% | 23.51% | 23.51% | 23.51% | 23.51% | 23.51% |
Ownership & Short Interest
Calculate Your Nanobiotix Investment Returns
Long-Term Investment Performance Analysis
Nanobiotix stock price in Jul 2016 was €16.92, A €1,000.00 lump sum investment in Nanobiotix made 9 years ago would be worth approximately €1,881.80 today, representing a solid return of 88.18%. This translates to an annualized return (CAGR) of 6.59%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is NANO's 52-week high and low?
- In the last 52 weeks, Nanobiotix reached a high of €47.66 (on May 18, 2026) and a low of €3.76 (on June 23, 2025).
- What is the market cap and P/E ratio for NANO?
- Curious about Nanobiotix's size and valuation? Its market capitalization stands at 1.39B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -79.72.
- Does NANO pay dividends? If so, what's the yield?
- As for dividends, Nanobiotix isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Nanobiotix's main competitors or similar companies to consider before investing?
When looking at Nanobiotix, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX7.61B Healthcare Biotechnology 1,368.91% 434.91% Dbv Technologies
DBV1.02B Healthcare Biotechnology 89.31% -17.08% TheraVet S.A
ALVETN/A Healthcare Biotechnology -89.74% -98.11% Inventiva S.A
IVA980.10M Healthcare Biotechnology 17.12% -17.79% Medincell S.A
MEDCL831.60M Healthcare Biotechnology 23.51% 23.51% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Nanobiotix? (e.g., ROE, Debt/Equity)
- To get a sense of Nanobiotix's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 28.36%, the Debt to Equity ratio from the most recent quarter is -1.13, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for NANO?
- Looking at Nanobiotix's growth, its revenue over the trailing twelve months (TTM) was €33M. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of NANO stock is held by insiders and institutions?
- Wondering who owns Nanobiotix stock? Company insiders (like executives and directors) hold about 16.26% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 31.64%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.